StreetAlpha.app
Home › Stocks › NRIX

Nurix Therapeutics, Inc. (NRIX)

$14.24
▼ −3.33%
LAST CLOSE · NOV 17

Nurix is a Brisbane, California biopharmaceutical company developing cancer and inflammation drugs that remove disease-causing proteins. It last closed at $14.24 on Nov 17, down 3.33% on the day. NRIX reports earnings on Wed, Jan 27, 2027. The average 12-month price target from 6 analysts is $32.00 (+124.7% from the last close), with a high of $36.00 and a low of $20.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell).

AI Auto Pilots
Is NRIX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$701.9M
+738.8% vs a year ago
Net income
$294.9M
42.0% margin
EPS (diluted)
$2.43
Free cash flow
$369.8M
52.7% margin
Valuation
Market cap
$1.6B
109.2M shares
P/E
5.9
Price over 12 month EPS
Price to sales
2.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$720.2M
At Aug 31
Shareholder equity
$968.3M
Shares outstanding
109.2M
At Sep 30
Fiscal year endsNovember
ExchangeNasdaq
Financials history
FY2021: $29.8M$29.8MFY2021FY2022: $38.6M$38.6MFY2022FY2023: $77.0M$77.0MFY2023FY2024: $54.5M$54.5MFY2024FY2025: $84.0M$84.0MFY2025

From NRIX's SEC filings, latest 10-Q for the period ending Aug 31, 2026 (filed Oct 13). Last 12 months adds up the four latest quarters.

Next report
Jan 27
2027 · Time not announced
Consensus EPS forecast
-$0.46
$287.9M revenue est.
Year-ago EPS
-$0.82
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
6 Buy0 Hold0 Sell
Each firm's latest rating on NRIX in the past 90 days
Average 12-month target
$32.00
▲ 124.7% upside

Based on 6 analysts who set a price target on NRIX in the past 90 days. The average target is $32.00, with a high of $36.00 and a low of $20.00, compared with the last close of $14.24.

Low $20.00Avg $32.00High $36.00
Blue marker: last close $14.24
Highest target$36.00
Average target$32.00
Lowest target$20.00
Latest rating changes
Wells FargoTarget lowered
Nov 4Buy$25 → $20
HC Wainwright & Co.Target raised
Oct 16Buy$34 → $36
RBC CapitalTarget lowered
Oct 13Buy$36 → $35
OppenheimerMaintained
Oct 13Buy$32
Truist SecuritiesTarget lowered
Oct 13Buy$34 → $33
DateFirmActionRatingPrice target
Nov 4Wells FargoTarget loweredBuy$25 → $20
Oct 16HC Wainwright & Co.Target raisedBuy$34 → $36
Oct 13RBC CapitalTarget loweredBuy$36 → $35
Oct 13OppenheimerMaintainedBuy$32
Oct 13Truist SecuritiesTarget loweredBuy$34 → $33
Loading…

Technical Analysis

NRIX · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 46% below its 20 day and 60% below its 50 day average. It is 41% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the Pivot S1 at $13.95, and the nearest resistance the Pivot at $14.40.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 10.1%/day
Key levels
$28.2352 week high+98.2%
$23.88100 day average+67.7%
$22.8050 day average+60.1%
$20.8120 day average+46.1%
$20.10200 day average+41.2%
$16.76Swing high (Nov 10)+17.7%
$14.70Pivot R1+3.2%
$14.40Pivot+1.1%
$14.24Last close
$13.95Pivot S1−2.0%
$12.4352 week low−12.7%
Indicators
RSI (14)24.21Oversold below 30Oversold
MACD-2.68Below its signal lineBearish
Stochastic2.2Near the bottom of its rangeOversold
ADX (14)38.1Trending down
Williams %R-99.1Oversold below −80, overbought above −20Oversold
CCI (20)-81.6Oversold below −100, overbought above 100Neutral
Rate of change−44.9%Change over 10 sessionsBearish
ATR (14)$1.44Typical daily range, 10.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NRIX

What happened before

See how NRIX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NRIX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NRIX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NRIX in the last 90 days.

Loading…

See today’s whale options flow across the market →

NRIX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲125 buying vs 81 selling
  • ▲Held by funds +2.1 pts
  • ▲Funds holding +22
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding233211+10.4%
In funds' top 1076+16.7%
Held by funds109.5%107.4%+2.1 pts
New / increased45 / 8044 / 67+12.6%
Reduced / sold out58 / 2363 / 28−11.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NRIX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRIX is in one of them and how their past NRIX trades turned out.

NRIX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NRIX in an article yet. Here's the latest on the wider market.

About Nurix Therapeutics

Nurix is a clinical stage biopharmaceutical company based in Brisbane, California. It develops medicines based on targeted protein degradation, a approach that removes disease-causing proteins, with a focus on cancer and inflammatory conditions. Its lead candidate, bexobrutideg, is being studied in patients with relapsed or refractory chronic lymphocytic leukemia. The company also works with large drug makers, including Gilead, Sanofi and Pfizer, on collaborations that use its platform, which combines DNA encoded libraries with artificial intelligence, to find new drug candidates.

Headquarters
Brisbane, CA
Founded
2012